Alexion Announces Creation of New Roles on Executive Leadership Team

– Anne-Marie Law becomes Chief Patient and Employee Experience
Officer –

– Aradhana Sarin, M.D., appointed as Chief Strategy and Business
Officer –

BOSTON–(BUSINESS WIRE)–Alexion
Pharmaceuticals, Inc.
(NASDAQ: ALXN) today announced the creation of
new roles within its executive leadership team. Anne-Marie Law has been
appointed to the newly created role of Chief Patient and Employee
Experience Officer. Aradhana Sarin, M.D., has been appointed to the
newly created role of Chief Strategy and Business Officer.

We continue to evolve the organization to meet the needs of our growing
business and stakeholder priorities,” said Ludwig Hantson, Ph.D., Chief
Executive Officer at Alexion. “The creation of these two new roles
underscores the importance of building the company to ensure long-term,
sustainable future growth and the central role that patients play in
everything we do at Alexion.”

Anne-Marie Law, Executive Vice President, Chief Patient and Employee
Experience Officer

Ms. Law has served as Executive Vice
President, Chief Human Resources Officer since joining Alexion in June
2017. Ms. Law is a human resources executive with more than 25 years of
experience at global corporations with a strong track record of driving
positive change and managing multi-national workforces in multiple
global locations. In her new role, Ms. Law will focus on bringing
together cross-functional and cross-geographical teams to fully
understand the patient journey in order to turn patient insights into
action and ensure that the company’s decisions are grounded in real-life
insights. She will combine this with her continued leadership of the
company’s human resources organization to cultivate world-class
leadership and innovation capabilities, integrating learnings from
stakeholders and improving the employee experience to, ultimately,
elevate the patient experience.

Anne-Marie has been critical in helping drive positive organizational
change across Alexion and establishing an organization built on high
performing, inclusive and aligned teams over the last year and a half,”
said Dr. Hantson. “I am confident that in this new role, Anne-Marie will
help ensure that our organization maintains its central focus on serving
patients as the company continues to grow and evolve, while also
increasing our capabilities and momentum in addressing patient needs.”

Aradhana Sarin, M.D., Executive Vice President, Chief Strategy and
Business Officer

Since joining Alexion in November 2017, Dr.
Sarin has served as Senior Vice President, Business Development and
Corporate Strategy. Dr. Sarin brings to Alexion more than 20 years of
experience at global financial institutions with extensive knowledge of
global healthcare systems as well as an excellent understanding of the
biopharmaceutical sector and deep transactional experience. In her time
at Alexion, Dr. Sarin has successfully led the company’s disciplined
business development efforts, overseeing five business development deals
that have been critical to rebuilding and diversifying Alexion’s
pipeline. She has also been responsible for ensuring that the company is
positioned to meet the strategic needs of its refocused corporate
strategy. Reporting to Dr. Hantson, this new role will be responsible
for overseeing the company’s corporate strategy, business development
and business operations, including corporate planning.

I am delighted to welcome Aradhana to our executive team. Her
leadership and strategic vision have already had a transformative impact
on the organization,” said Dr. Hantson. “This new role will be critical
to ensuring continued growth and executional excellence across our
increasingly complex and diverse portfolio as we work to achieve our
Four Pillars of growth, building durable blockbuster franchises in PNH
and atypical HUS, metabolics, neurology and FcRn.”

About Alexion
Alexion is a global biopharmaceutical company
focused on serving patients and families affected by rare diseases
through the discovery, development and commercialization of
life-changing therapies. As the global leader in complement biology and
inhibition for more than 20 years, Alexion has developed and
commercializes two approved complement inhibitors to treat patients with
paroxysmal nocturnal hemoglobinuria (PNH) as well as the first and only
approved complement inhibitor to treat atypical hemolytic uremic
syndrome (aHUS) and anti-acetylcholine receptor (AchR) antibody-positive
generalized myasthenia gravis (gMG), and is also developing it for
patients with neuromyelitis optica spectrum disorder (NMOSD). Alexion
also has two highly innovative enzyme replacement therapies for patients
with life-threatening and ultra-rare metabolic disorders,
hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D). In
addition, the company is developing several mid-to-late-stage therapies,
including a second complement inhibitor, a copper-binding agent for
Wilson disease and an anti-neonatal Fc receptor (FcRn) antibody for rare
Immunoglobulin G (IgG)-mediated diseases. Alexion focuses its research
efforts on novel molecules and targets in the complement cascade and its
development efforts on the core therapeutic areas of hematology,
nephrology, neurology, and metabolic disorders. Alexion has been named
to the Forbes list of the World’s Most Innovative Companies seven
years in a row and is headquartered in Boston, Massachusetts’ Innovation
District. The company also has offices around the globe and serves
patients in more than 50 countries. This press release and further
information about Alexion can be found at: www.alexion.com.

[ALXN-G]

Forward-Looking Statement
This press release contains
forward-looking statements, including statements related to: the Company
continues to evolve to meet the needs of its growing business and
stakeholder priorities; the Company continues to grow and it is
increasing capabilities and momentum in addressing patient needs; the
Company is working to ensure continued growth and executional excellence
across the increasingly complex and diverse portfolio; and the Company
expects to achieve its Four Pillars of growth, building durable
blockbuster franchises in PNH and atypical HUS, metabolics, neurology
and FcRn. Forward-looking statements are subject to factors that may
cause Alexion’s results and plans to differ materially from those
forward-looking statements, including for example: our dependence on
sales from our principal product (SOLIRIS® (eculizumab)); our
ability to facilitate the timely conversion of PNH patients (and any
future indications) from SOLIRIS to ULTOMIRIS™ (ravulizumab-cwvz);
payer, physician and patient acceptance of ULTOMIRIS as an alternative
to SOLIRIS; appropriate pricing for ULTOMIRIS; our ability to grow
revenues with sales due to our proposed blockbuster franchises; future
competition from biosimilars and novel products; decisions of regulatory
authorities regarding the adequacy of our research, marketing approval
or material limitations on the marketing of our products; delays or
failure of product candidates to obtain regulatory approval; delays or
the inability to launch product candidates due to regulatory
restrictions, anticipated expense or other matters; interruptions or
failures in the manufacture and supply of our products and our product
candidates; failure to satisfactorily address matters raised by the FDA
and other regulatory agencies; results in early stage clinical trials
may not be indicative of full results or results from later stage or
larger clinical trials (or broader patient populations) and do not
ensure regulatory approval; the possibility that results of clinical
trials are not predictive of safety and efficacy and potency of our
products (or we fail to adequately operate or manage our clinical
trials) which could cause us to halt trials, delay or prevent us from
making regulatory approval filings or result in denial of approval of
our product candidates; unexpected delays in clinical trials; unexpected
concerns that may arise from additional data or analysis obtained during
clinical trials; future product improvements may not be realized due to
expense or feasibility or other factors; uncertainty of long-term
success in developing, licensing or acquiring other product candidates
or additional indications for existing products; inability to complete
planned acquisitions due to failure of regulatory approval or material
changes in target or otherwise; inability to complete acquisitions and
investments due to increased competition for technology; the possibility
that current rates of adoption of our products are not sustained; the
adequacy of our pharmacovigilance and drug safety reporting processes;
failure to protect and enforce our data, intellectual property and
proprietary rights and the risks and uncertainties relating to
intellectual property claims, lawsuits and challenges against us; the
risk that third party payors (including governmental agencies) will not
reimburse or continue to reimburse for the use of our products at
acceptable rates or at all; failure to realize the benefits and
potential of investments, collaborations, licenses and acquisitions; the
possibility that expected tax benefits will not be realized; assessment
of impact of recent accounting pronouncements; potential declines in
sovereign credit ratings or sovereign defaults in countries where we
sell our products; delay of collection or reduction in reimbursement due
to adverse economic conditions or changes in government and private
insurer regulations and approaches to reimbursement; uncertainties
surrounding legal proceedings, company investigations and government
investigations, including investigations of Alexion by the U.S.
Securities and Exchange Commission (SEC) and U.S. Department of Justice;
the risk that estimates regarding the number of patients with PNH, aHUS,
gMG, HPP and LAL-D and other future indications we are pursuing are
inaccurate; the risks of changing foreign exchange rates; risks relating
to the potential effects of the Company’s restructuring; risks related
to the acquisition of Syntimmune and other companies and co-development
efforts; risks related to cybersecurity matters or unauthorized access
to our computer networks; and a variety of other risks set forth from
time to time in Alexion’s filings with the SEC, including but not
limited to the risks discussed in Alexion’s Annual Report on Form 10-K
for the year ended December 31, 2018 and in our other filings with the
SEC. Alexion disclaims any obligation to update any of these
forward-looking statements to reflect events or circumstances after the
date hereof, except when a duty arises under law.

Contacts

Alexion:
Media
Megan Goulart, 857-338-8634
Senior
Director, Corporate Communications

Investors
Susan Altschuller, Ph.D., 857-338-8788
Vice
President, Investor Relations